Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates, which act as ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

The funds will support multiple new and ongoing clinical trials of Tilt's oncolytic adenoviral therapy TILT-123.

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Citi downgraded both AbbVie (NYSE:ABBV) and Merck (NSE:PROR) to Neutral in separate notes Wednesday, citing long-term growth concerns and late-stage pipeline limitations as headwinds for the ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

On May 12th the president signed an executive order that seeks to force drugmakers to reduce their prices in America to align ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for ...